Gefitinib

Gefitinib
Clinical data
Pronunciation	/ɡɛˈfɪtɪnɪb/
Trade names	Iressa, others
Other names	ZD1839
AHFS/Drugs.com	Monograph
MedlinePlus	a607002
License data	EU EMA: by INN; US DailyMed: Gefitinib;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	L01EB01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	59% (oral)
Protein binding	90%
Metabolism	Liver (mainly CYP3A4)
Elimination half-life	6–49 hours
Excretion	Feces
Identifiers
	IUPAC name N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;
CAS Number	184475-35-2 ;
PubChem CID	123631;
IUPHAR/BPS	4941;
DrugBank	DB00317 ;
ChemSpider	110217 ;
UNII	S65743JHBS;
KEGG	D01977 ;
ChEBI	CHEBI:49668 ;
ChEMBL	ChEMBL939 ;
CompTox Dashboard (EPA)	DTXSID8041034 ;
ECHA InfoCard	100.171.043
Chemical and physical data
Formula	C22H24ClFN4O3
Molar mass	446.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCCOc2c(OC)cc3ncnc(c3c2)Nc4cc(Cl)c(F)cc4;
	InChI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) ; Key:XGALLCVXEZPNRQ-UHFFFAOYSA-N ;
	(verify)

Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.

It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.